Additionally, TET2- and IDH-mutant AMLs exhibit significantly reduced 5hmC levels within IDH-mutant DNA hypermethylated regions when compared with AML patient samples that were wild-type for TET2 and IDH [53], collectively suggesting that the effects of mutant-IDH on DNA methylation are driven in part by 2-HG inhibition of TET2. The gene discussed is TET2; the disease is acute myeloid leukemia.